{
    "relation": [
        [
            "",
            "LPV/r + FTC/TDF",
            "LPV/r + RAL"
        ],
        [
            "Description",
            "lopinavir/ritonavir 400/100 mg tablet twice-daily + co-formulated emtricitabine/tenofovir disoproxil fumarate 200/300 mg once-daily",
            "lopinavir/ritonavir 400/100 mg tablet twice-daily + raltegravir 400 mg twice-daily"
        ]
    ],
    "pageTitle": "Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL) - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00711009?sect=Xl015&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042988860.88/warc/CC-MAIN-20150728002308-00082-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 864597209,
    "recordOffset": 864581600,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups 3 additional participants were randomized but did not receive study drug and therefore were not included in the analyses. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: lopinavir/ritonavir (LPV/r) Drug: emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) Drug: raltegravir (RAL) Interventions: Human Immunodeficiency Virus Infection Condition: Allocation:\u00a0Randomized; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Open\u00a0Label; \u00a0 Primary\u00a0Purpose:\u00a0Treatment Study Design: Interventional Study Type:",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 LPV/r + FTC/TDF \u00a0 \u00a0 LPV/r + RAL \u00a0 STARTED \u00a0 \u00a0 105 \u00a0 \u00a0 101 \u00a0 COMPLETED \u00a0 \u00a0 90 \u00a0 \u00a0 82 \u00a0 NOT COMPLETED \u00a0 \u00a0 15 \u00a0 \u00a0 19 \u00a0 Adverse Event/HIV-Related Event \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 4 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 5 \u00a0 Withdrawal by Subject \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 4 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 2 \u00a0 Lost to Follow-up \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 3 \u00a0",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}